Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: A steroid-sparing regimen

Rheumatology

Volumn 51, Issue 3, 2012, Pages 476-481

  Ezeonyeji, Amara N ^a   Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

B cell depletion therapy; BILAG index; Disease activity; Early treatment; SLE; Steroids

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; PROTEIN; RITUXIMAB;

ABSENT RIGHT SUPERIOR VENA CAVA; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; B CELL DEPLETION THERAPY; B LYMPHOCYTE; CELL THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DETERIORATION; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE INCREASE; EARLY INTERVENTION; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; FEMALE; HUMAN; LOW DRUG DOSE; LYMPHOCYTE COUNT; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; B-LYMPHOCYTES; BLOOD SEDIMENTATION; CASE-CONTROL STUDIES; COMPLEMENT C3; CYCLOPHOSPHAMIDE; DNA; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MIDDLE AGED; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857562039     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker337     Document Type: Article

References (11)

1. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62: 222-33.
2. Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009;60(Suppl. 10):1149.
3. Lu TY, Ng KP, Cambridge G et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
4. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458-66.
5. Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24: 3717-23.
6. Rahman P, Gladman DD, Urowitz MB et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
7. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
8. Isenberg DA, Rahman A, Allen E et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902-6.
9. Cresswell L, Yee CS, Farewell V et al. Numerical scoring for the classic BILAG index. Rheumatology 2009;48: 1548-52.
10. Favas C, Isenberg DA. B-cell-depletion therapy in SLE-what are the current prospects for its acceptance? Nat Rev Rheumatol 2009;5:711-6.
11. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology 2000;39:238-44.